Quick Answer
Summit Therapeutics Inc. reported Diluted EPS of $1.44 per share (loss) for fiscal year 2025.
Summit Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.44 | -364.5% |
| 2024 | -$0.31 | +68.7% |
| 2023 | -$0.99 | -141.5% |
| 2022 | -$0.41 | +38.8% |
| 2021 | -$0.67 | +11.8% |
| 2020 | -$0.76 | +14.6% |
| 2019 | -$0.89 | -241.3% |
| 2019 | $0.63 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.31 | -287.5% | +59.2% |
| June 30, 2025 | -$0.76 | -744.4% | -744.4% |
| March 31, 2025 | -$0.09 | -50.0% | -12.5% |
| September 30, 2024 | -$0.08 | -166.7% | +11.1% |
| June 30, 2024 | -$0.09 | -350.0% | -50.0% |
| March 31, 2024 | -$0.06 | +95.8% | -100.0% |
| September 30, 2023 | -$0.03 | +70.0% | -50.0% |
| June 30, 2023 | -$0.02 | +83.3% | +98.6% |
- Summit Therapeutics Inc. showed a decrease of -364.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Summit Therapeutics Inc.’s diluted eps has declined by 328.6% (from $0.63 per share to $1.44 per share (loss)).
- The most recent figure is from Summit Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: